{"abstract": "Seeking to fend off a hostile takeover bid by Sanofi-Aventis, the biotechnology company Genzyme argued strenuously that it was worth far more than the $18.5 billion that the French drug maker is offering.", "web_url": "https://dealbook.nytimes.com/2010/10/22/genzyme-makes-case-that-sanofi-bid-is-too-low/", "snippet": "Seeking to fend off a hostile takeover bid by Sanofi-Aventis, the biotechnology company Genzyme argued strenuously that it was worth far more than the $18.5 billion that the French drug maker is offering.", "lead_paragraph": "Andrew Pollack, a DealBook colleague, reports:", "source": "The New York Times", "multimedia": [], "headline": {"main": "Genzyme Makes Case That Sanofi Bid Is Too Low", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Genzyme Corp", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Sanofi-Aventis SA", "rank": 2, "major": "N"}], "pub_date": "2010-10-22T22:41:57+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/9881978c-3547-5fee-8940-0fd9ffd5c1e8", "word_count": 557, "uri": "nyt://article/9881978c-3547-5fee-8940-0fd9ffd5c1e8"}